TY - JOUR
T1 - Corrigendum: Targeting complement pathways in polytrauma- And sepsis-induced multiple-organ dysfunction (Frontiers Media S.A. (2019) 10 (543) DOI: 10.3389/fimmu.2019.00543)
AU - Karasu, Ebru
AU - Nilsson, Bo
AU - Köhl, Jörg
AU - Lambris, John D.
AU - Huber-Lang, Markus
N1 - Publisher Copyright:
Copyright © 2019 Karasu, Nilsson, Köhl, Lambris and Huber-Lang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/5/3
Y1 - 2019/5/3
N2 - In the original article, we neglected to include a conflict of interest statement of Prof. John D. Lambris. JL is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogs, such as AMY-101) and is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. JL is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals [i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives]. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
AB - In the original article, we neglected to include a conflict of interest statement of Prof. John D. Lambris. JL is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogs, such as AMY-101) and is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. JL is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals [i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives]. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
UR - http://www.scopus.com/inward/record.url?scp=85066927596&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2019.00994
DO - 10.3389/fimmu.2019.00994
M3 - Comments/Debates
C2 - 31130967
AN - SCOPUS:85066927596
SN - 1664-3224
VL - 10
JO - Frontiers in Immunology
JF - Frontiers in Immunology
IS - MAY
M1 - 994
ER -
